Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HOLX vs DGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: HOLX 3 – 3 DGX Matrix Metrics: HOLX 6 – 4 DGX

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Quest Diagnostics Inc. (DGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas DGX carries 50.5/100 (HOLD) at $258.28 (21.6x Forward P/E, 14.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs DGX
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
DGX NYSE
Quest Diagnostics Inc.
Services-Medical Laboratories
$258.28
-0.31% 1D
Market Cap $28.5B
TTM Revenue $11.8B
Forward P/E 21.6x
Beta / 30D Vol -0.04β · 20% Vol
Unified Composite Score
50.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 56.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $254.57 · SMA50: $243.73

6-Pillar Scorecard Institutional Category Breakdown (HOLX 3 – 3 DGX)

Columns: Metric · HOLX · DGX
1. Valuation Multiples DGX
Forward P/E 20.1x 21.6x
Trailing P/E 31.4x 25.8x
PEG Ratio 1.66x 1.68x
EV / Revenue 4.1x 2.9x
2. Growth & Scale DGX
Revenue Growth (YoY) +2.5% +10.0%
Earnings Growth (YoY) -9.2% +28.7%
TTM Revenue (USD) $4.13B $11.8B
Market Cap $16.9B $28.5B
3. Profitability & Quality HOLX
Gross Margin 60.4% 33.2%
Operating Margin 23.0% 14.9%
Net Profit Margin 13.2% 9.5%
Return on Equity (ROE) 10.9% 15.3%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA $1.38B
Cash Flow Margin 32.7% EBITDA Mgn 11.6%
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE $5.49B Net Debt (0.82x D/E)
Dividend Yield None (0.00%) 1.30%
5. Options & Positioning DGX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 6.3% (3rd %ile) 29.7% (16th %ile)
Put/Call OI Skew 6.20x (Put-Skewed) 0.14x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat HOLX
OpEx & R&D Intensity 37.4% of Rev ($1.54B) 18.3% of Rev ($2.17B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (6) vs DGX (4)
Institutional Metric HOLX DGX Criterion Row Edge
Market Capitalization
Scale
$16.9B $28.5B Larger Scale DGX
Trailing P/E Ratio
Valuation
31.4x 25.8x Lower Multiple DGX
Forward P/E Ratio
Valuation
20.1x 21.6x Lower Multiple HOLX
Revenue Growth (YoY)
Growth
+2.5% +10.0% Higher Growth DGX
Operating Margin (TTM)
Profitability
23.0% 14.9% Higher Margin HOLX
Net Profit Margin
Profitability
13.2% 9.5% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
10.9% 15.3% Higher ROE DGX
52-Week Range Position
Momentum
100% ($52–$76) 95% ($171–$263) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol -0.04β · 20% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 50.5 / 100 (HOLD) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B $11.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% 33.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev 1.68x PEG · 2.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) $1.38B ($5.49B Net Debt (0.82x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +2.8 pp
HOLX: +0.34% · DGX: -2.46%
3M Horizon DGX +12.54 pp
HOLX: +1.94% · DGX: +14.48%
6M Horizon DGX +4.51 pp
HOLX: +2.48% · DGX: +6.99%
1Y Horizon DGX +4.51 pp
HOLX: +2.48% · DGX: +6.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs DGX. Trailing 12-month operating profitability (HOLX 23.0% vs DGX 14.9%) and valuation multiples (HOLX 20.1x vs DGX 21.6x Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
DGX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11.8B
Gross Margin33.2%
Op. Margin14.9%
ROE / Fwd P/E15.3% · 21.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DGX CONSOLIDATION
75d in phase · OBV ACCUMULATION
Current IV 29.7%
IV Percentile 16th %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $259.69 · IV 28.5%

DGX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($25,969)

Compare $25,969 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 28.5% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $260 / $280 Bull Call Spread

Buy 1x $260C · Sell 1x $280C · 28d

Net Entry $510 Debit
T+5d @ +5% Move +$418 (+82%)
Max Risk / Buffer $510 Capped
5d Edge & Liquidity 1.2x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $250 / $240 Bull Put Spread

Sell 1x $250P · Buy 1x $240P · 28d

Net Entry $320 Credit
Max Credit / Yield +$320 (+47.1% RoM)
Max Risk / Buffer -5.0% Cushion ($680 Mgn)
5d Edge & Liquidity 69% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $260 / $250 Bear Put Spread

Buy 1x $260P · Sell 1x $250P · 28d

Net Entry $268 Debit
T+5d @ -5% Drop +$259 (+97%)
Max Risk / Buffer $268 Capped
5d Edge & Liquidity 1.4x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
DGX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $28.5B market capitalization and 14.9% operating margin.
OpEx & R&D Reinvestment 18.3% of Rev ($2.17B)
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs DGX Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Quest Diagnostics Inc. (DGX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas DGX carries 50.5/100 (HOLD) at $258.28 (21.6x Forward P/E, 14.9% operating margin). Technically, HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure) and DGX sits in a Markup phase (RSI 60.8, CONSOLIDATION options structure).

DGX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with DGX at +10.0% YoY revenue growth and +28.7% YoY earnings growth on $11.8B TTM revenue (33.2% gross margin, 14.9% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $11.8B for DGX. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 18.3% of Rev ($2.17B) (0 disclosures) for DGX.

DGX screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas DGX trades at 21.6x Forward P/E, 25.8x Trailing P/E, 1.68x PEG, and 2.9x EV/Revenue (11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus DGX (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, DGX carries 29.7% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.